The trial conducted by Hartmut Döhner and his research group has shown that, compared to placebo, oral azacitidine improved overall survival in patients with acute myeloid leukemia (AML) in first remission after chemotherapy who were not candidates for stem cell transplantation. This analysis found that the azacitidine-associated survival improvement was independent of NPM1 and FLT3 mutational status.
These results confirm that AML patients who are not candidates for stem cell transplantation benefit from oral azacitidine regardless of mutational status, cytogenetic risk, or residual disease status.
